www.fdanews.com/articles/97889-somatuline-depot-receives-marketing-approval-in-the-u-s-for-the-treatment-of-acromegaly
Somatuline Depot Receives Marketing Approval in the U.S. for the Treatment of Acromegaly
August 31, 2007
Ipsen announced that the FDA has approved for marketing Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg in the U.S.
Ipsen